Saxon Interests Inc. Lowers Stock Position in Anavex Life Sciences Corp. (NASDAQ:AVXL)

Saxon Interests Inc. decreased its position in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) by 6.2% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 25,687 shares of the biotechnology company’s stock after selling 1,689 shares during the period. Saxon Interests Inc.’s holdings in Anavex Life Sciences were worth $276,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Barclays PLC lifted its stake in Anavex Life Sciences by 70.4% in the third quarter. Barclays PLC now owns 155,179 shares of the biotechnology company’s stock worth $882,000 after purchasing an additional 64,101 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in Anavex Life Sciences by 2.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 665,976 shares of the biotechnology company’s stock worth $3,783,000 after acquiring an additional 14,892 shares during the last quarter. Renaissance Technologies LLC increased its stake in Anavex Life Sciences by 483.8% in the 2nd quarter. Renaissance Technologies LLC now owns 466,437 shares of the biotechnology company’s stock worth $1,968,000 after purchasing an additional 386,537 shares during the period. Franklin Resources Inc. lifted its position in Anavex Life Sciences by 6.7% in the third quarter. Franklin Resources Inc. now owns 58,557 shares of the biotechnology company’s stock valued at $317,000 after purchasing an additional 3,674 shares during the last quarter. Finally, Nwam LLC purchased a new stake in shares of Anavex Life Sciences during the third quarter valued at approximately $5,172,000. Institutional investors own 31.55% of the company’s stock.

Anavex Life Sciences Stock Down 4.6 %

Shares of AVXL stock opened at $9.69 on Friday. The firm has a market capitalization of $821.48 million, a price-to-earnings ratio of -18.80 and a beta of 0.70. The stock has a fifty day moving average of $9.73 and a 200 day moving average of $7.15. Anavex Life Sciences Corp. has a 52 week low of $3.25 and a 52 week high of $14.44.

Anavex Life Sciences (NASDAQ:AVXL) last posted its earnings results on Monday, December 23rd. The biotechnology company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.03. Equities research analysts anticipate that Anavex Life Sciences Corp. will post -0.73 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently commented on AVXL shares. HC Wainwright lifted their target price on shares of Anavex Life Sciences from $40.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, December 26th. D. Boral Capital reissued a “buy” rating and issued a $46.00 target price on shares of Anavex Life Sciences in a research note on Monday.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.